Lioudmila Tchistiakova

This inventor holds 36 USPTO granted patents and 8 published patent applications, plus 5 CIPO patents and 8 EPO patents, primarily in Antibody Engineering. Top assignees: Wyeth, Pfizer Corporation, Elasmogen Limited. Active years: 2009-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lioudmila Tchistiakova. Retrieved from https://idiyas.com/inventor/lioudmila-tchistiakova

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 36 (Patent Applications = 8)

% Patents Active = 41.7

CIPO Patents = 5 (Patent Applications = 6)

EPO Patents = 8 (Patent Applications = 14)

Average Co-Inventor Count = 7.4

ph-index = 11

Forward Citations = 457(Granted Patents)

Location History:

Andover, MA (US) (2009 - 2021)
Stoneham, MA (US) (2015 - 2023)
Cambridge, MA (US) (2016 - 2023)

Company Filing History:

Janssen Sciences Ireland Uc

patents

5. 2 out of 51

University of Aberdeen

patents

6. 1 out of 538

Beth Israel Deaconess Medical Center, Inc.

University of Pennsylvania

patents

where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...

Areas of Expertise:

Antibody Drug Conjugates

Bispecific Antibodies

Humanized Antibodies

Single Domain Binding Molecule

GDF8 Antagonists

Anti-IL-13 Receptor

Immunotherapy

Muscle Wasting Treatment

Polynucleotides

Nucleic Acids

Pharmaceutical Compositions

Tumor Targeting

36 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12371507 - CDCP1 antibodies and antibody drug conjugates (2025-07-29),

2. 11692025 - Single domain binding molecule (2023-07-04),

3. 11578428 - Humanized antibodies (2023-02-14),

4. 11434292 - Antibodies specific for CD3 and uses thereof (2022-09-06),

5. 11147852 - Engineered antibody constant regions for site-specific conjugation and methods and uses therefor (2021-10-19),

6. 11034756 - Single domain binding molecule (2021-06-15),

7. 10647756 - Humanized antibodies (2020-05-12),

8. 10392438 - Bispecific antibodies (2019-08-27),

9. 10287341 - Single domain binding molecule (2019-05-14),

10. 10189896 - Antibody to GDF8 and uses thereof (2019-01-29),

11. 9926368 - Method for treating muscle wasting syndrome using antagonist antibodies against GDF-8 (2018-03-27),

12. 9902771 - Anti-5T4 antibodies and uses thereof (2018-02-27),

13. 9884921 - Bispecific heterodimeric diabodies and uses thereof (2018-02-06),

14. 9850301 - Antibody to GDF8 and uses thereof (2017-12-26),

15. 9828428 - Anti-IL-13 receptor alpha 2 antibodies and antibody-drug conjugates (2017-11-28),

Title: Innovations and Contributions of Lioudmila Tchistiakova

Introduction

Lioudmila Tchistiakova, based in Andover, MA, has made significant strides in the field of biotechnology. With an impressive portfolio of 35 patents, Tchistiakova has demonstrated a strong commitment to advancing scientific knowledge and innovation.

Latest Patents

Among her latest patents is the invention of a single domain binding molecule, which features the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4. This specific binding molecule boasts a high affinity for human serum albumin (HSA) due to its meticulously defined amino acid sequences. Additionally, she has contributed to the field by developing humanized antibodies, which incorporate human germline residues into the complementarity determining regions (CDRs) of non-human donor antibodies. These advancements include libraries of antibody variable domains and methods for screening for humanized antibodies.

Career Highlights

Throughout her career, Lioudmila has had significant roles at prominent companies, including Wyeth and Pfizer Corporation. Her work in these leading organizations has allowed her to contribute to various groundbreaking projects that focus on enhancing therapeutic methods in biotechnology.

Collaborations

Lioudmila Tchistiakova has collaborated with renowned professionals such as Xiang-Yang Tan and Kimberly Ann Marquette. These collaborations have further enriched her perspective and expertise in the field, enhancing the quality of her innovative contributions.

Conclusion

Lioudmila Tchistiakova stands out as a pioneering inventor in biotechnology. Her extensive number of patents and collaborative efforts underline her valuable contributions to innovation in the sector. As she continues her work, her impact on scientific advancements and therapeutic solutions is sure to grow.

Profile summary based on public USPTO records.